Pular para o conteúdo principal
Ranking Invest

OCUL - Ocular Therapeutix, Inc.

Segmento: HealthcareOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 123.93 Mi
Valor de Mercado
$ 2.30 Bi
Desconto (AV)-1959.8%
IVR
-0.05A companhia vale -0,05 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.31O valuation alternativo equivale a -31% do valor de mercado da companhia.
MLL
-0.31O lucro líquido dos controladores em 16 trimestres equivale a -31% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 520.04 Mi

Dívida Líquida

-$ 598.64 Mi

L4T

-$ 301.45 Mi

MM4T

-592.85%

Indicadores Básicos

ROE

-57.97%

Índices de Previsibilidade

Receita Líquida

D0.10

Lucro

C0.31

Margem

C0.45

Índices de Tendência

Receita Líquida

D-2.45

Lucro

G-10.24

Margem

G-9.74

Índices de Endividamento

DIV/PAT

-1.15

DIV/L4T

1.99

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.